{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:06:46Z","timestamp":1761743206410,"version":"3.37.0"},"reference-count":31,"publisher":"FapUNIFESP (SciELO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p>CONTEXT: Systemic arterial hypertension is part of the metabolic syndrome resulting from obesity. OBJECTIVE: To evaluate the effect of sibutramine on overweight and obese patients' blood pressure through a systematic review. METHODS: All the studies included needed to be randomized controlled trials. The methodological quality of the selected trials was assessed using the criteria described in the Cochrane Handbook. The participants were overweight and obese patients; the intervention was sibutramine compared with placebo. The primary outcome measurement was systolic and diastolic blood pressure and the secondary measurement was blood pressure. Studies were identified by searching the following sources: Literatura Latino-Americana e do Caribe em Ci\u00eancias da Sa\u00fade (Lilacs), Medline, Cochrane reviews, manual searches, personal communication and contact with the pharmaceutical industry. There were no language, date or other restrictions. Data collection and extraction was performed by two reviewers, who independently obtained the full articles of all eligible papers. RESULTS: Three meta-analyses were produced: 1) systolic blood pressure outcome (eight studies) did not show statistical significance between sibutramine and placebo: weighted mean difference (WMD) 1.57, confidence interval (CI) -0.03 to 3.18; 2) diastolic blood pressure outcome (ten studies) did not show statistical significance between sibutramine and placebo: WMD 1.13, CI -0.49 to 2.76; 3) blood pressure outcome (two studies) also did not show statistical significance between the groups: relative risk (RR) 0.69, CI 0.07 to 7.01. CONCLUSIONS: The meta-analyses presented in this systematic review show that sibutramine does not have a statistically significant effect on blood pressure, compared with placebo.<\/jats:p>","DOI":"10.1590\/s1516-31802008000600010","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T22:08:34Z","timestamp":1236204514000},"page":"342-346","source":"Crossref","is-referenced-by-count":5,"title":["Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis"],"prefix":"10.1590","volume":"126","author":[{"given":"Hernani Pinto de","family":"Lemos J\u00fanior","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro Nagib","family":"Atallah","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Luis Alves de","family":"Lemos","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0950-351X(05)80287-3","article-title":"The epidemiology of obesity","volume":"8","author":"Hodge AM","year":"1994","journal-title":"Baillieres Clin Endocrinol Metab."},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1210\/jcem-54-2-254","article-title":"Relation of body fat distribution to metabolic complications of obesity","volume":"54","author":"Kissebah AH","year":"1982","journal-title":"J Clin Endocrinol Metab."},{"issue":"6428","key":"ref3","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/bmj.288.6428.1401","article-title":"Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913","volume":"288","author":"Larsson B","year":"1984","journal-title":"Br Med J (Clin Res Ed)."},{"key":"ref4","first-page":"65","article-title":"Insulin resistance in hypertension-a relationship with consequences?","volume":"735","author":"Berne C","year":"1991","journal-title":"J Intern Med Suppl."},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0895-7061(94)00206-Q","article-title":"Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men","volume":"8","author":"Moan A","year":"1995","journal-title":"Am J Hypertens."},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.HYP.23.3.381","article-title":"Dahl Memorial Lecture: Renal and cardiovascular mechanisms of hypertension in obesity","volume":"23","author":"Hall JE","year":"1994","journal-title":"Hypertension."},{"key":"ref7","first-page":"255","article-title":"Mechanisms of obesity-induced hypertension","volume":"11","author":"Hall JE","year":"1996","journal-title":"News Physiol Sci."},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.ijo.0801059","article-title":"The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction","volume":"23","author":"Hansen DL","year":"1999","journal-title":"Int J Obes Relat Metab Disord."},{"issue":"9248","key":"ref9","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James WP","year":"2000","journal-title":"Lancet."},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","article-title":"Effects of sibutramine on resting metabolic rate and weight loss in overweight women","volume":"6","author":"Seagle HM","year":"1998","journal-title":"Obes Res."},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(24)37090-9","article-title":"In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor","volume":"283","author":"Gundlah C","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"key":"ref12","series-title":"The Cochrane Library, Issue 2","volume-title":"Cochrane Reviewers' Handbook 4.1.5 [updated April 2002]","author":"Clarke M","year":"2002"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz KF","year":"1995","journal-title":"JAMA."},{"issue":"7414","key":"ref14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","journal-title":"BMJ."},{"key":"ref15","series-title":"Review Manager (RevMan) [Computer program]: Version 4.0.","volume-title":"Cochrane Reviewers' Handbook 4.0.","author":"Clarke M","year":"1999"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000047310","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients","volume":"94","author":"Hazenberg BP","year":"2000","journal-title":"Cardiology."},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","article-title":"A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity","volume":"24","author":"Fangh\u00e4nel G","year":"2000","journal-title":"Int J Obes Relat Metab Disord."},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0066-782X2002000200006","article-title":"Effects of sibutramine on the treatment of obesity in patients with arterial hypertension","volume":"78","author":"Faria AN","year":"2002","journal-title":"Arq Bras Cardiol."},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka K","year":"2000","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","article-title":"Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study","volume":"90","author":"Godoy-Matos A","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.jhh.1001299","article-title":"Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial","volume":"16","author":"Sramek JJ","year":"2002","journal-title":"J Hum Hypertens."},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mhj.2002.124403","article-title":"Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction","volume":"144","author":"Zannad F","year":"2002","journal-title":"Am Heart J."},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum M","year":"1999","journal-title":"Am J Med."},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/oby.2000.10","article-title":"Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population","volume":"8","author":"Cuellar GE","year":"2000","journal-title":"Obes Res."},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","article-title":"Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors","volume":"16","author":"McMahon FG","year":"2002","journal-title":"J Hum Hypertens."},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study","volume":"2","author":"Finer N","year":"2000","journal-title":"Diabetes Obes Metab."},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon FG","year":"2000","journal-title":"Arch Intern Med."},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/030079905X38132","article-title":"A review of the metabolic effects of sibutramine","volume":"21","author":"Filippatos TD","year":"2005","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"ref29","first-page":"CD004094","article-title":"Long-term pharmacotherapy for obesity and overweight","author":"Padwal R","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"issue":"7631","key":"ref30","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker D","year":"2007","journal-title":"BMJ."},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archinte.168.6.571","article-title":"Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis","volume":"168","author":"Horvath K","year":"2008","journal-title":"Arch Intern Med."}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v126n6\/10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:55:45Z","timestamp":1738976145000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802008000600010&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S1516-31802008000600010"],"URL":"https:\/\/doi.org\/10.1590\/s1516-31802008000600010","relation":{},"ISSN":["1516-3180"],"issn-type":[{"type":"electronic","value":"1516-3180"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}